{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["96(28)"],"submitter":["Li S"],"pubmed_abstract":["<h4>Background</h4>The high worldwide prevalence of chronic kidney disease (CKD) is a critical health problem and the development of more effective therapies is urgently needed. We conducted a randomized, double-blinded, placebo-controlled clinical trial from October 2010 to December 2012 to assess whether Fu-Zheng-Qu-Zhuo oral liquid (FZQZ) has a beneficial effect in preventing CKD progression when added to standard integrated therapies.<h4>Methods</h4>Patients with CKD stage 3 to 4 from 3 hospitals in Beijing, China were enrolled. Patients were randomly assigned to the FZQZ or placebo groups and were treated with standard integrated therapy plus FZQZ or placebo (20 mL each time, 3 times/d) for 12 months. Patients received post-trial follow-up until October 2014. The primary outcome was t"],"journal":["Medicine"],"pagination":["e7448"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5515754"],"repository":["biostudies-literature"],"pubmed_title":["Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial."],"pmcid":["PMC5515754"],"pubmed_authors":["Zhang NN","Lian FM","Dai XW","Li S","Kong LX","Pei K","Huo BM","Rao XR","Wang XJ","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.","description":"<h4>Background</h4>The high worldwide prevalence of chronic kidney disease (CKD) is a critical health problem and the development of more effective therapies is urgently needed. We conducted a randomized, double-blinded, placebo-controlled clinical trial from October 2010 to December 2012 to assess whether Fu-Zheng-Qu-Zhuo oral liquid (FZQZ) has a beneficial effect in preventing CKD progression when added to standard integrated therapies.<h4>Methods</h4>Patients with CKD stage 3 to 4 from 3 hospitals in Beijing, China were enrolled. Patients were randomly assigned to the FZQZ or placebo groups and were treated with standard integrated therapy plus FZQZ or placebo (20 mL each time, 3 times/d) for 12 months. Patients received post-trial follow-up until October 2014. The primary outcome was t","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2026-05-05T11:04:44.824Z","creation":"2019-03-27T02:50:49Z"},"accession":"S-EPMC5515754","cross_references":{"pubmed":["28700482"],"doi":["10.1097/MD.0000000000007448"]}}